Company
BioAge Labs
Company Snapshot
Company/IR framing; not an investment view.
Filing index is treated as navigation/context, not a substitute for full filing analysis.
Shown only at broad geography level for this prototype.
Company-described positioning.
Signal mapping, not clinical proof.
Independent context is limited and not used as efficacy proof.
Source cleanup pass retained official, IR, registry, and independent context sources.
Medium for identity, IR navigation, and registry facts; lower for company-reported biomarker/program claims.
Why It Matters
BioAge is a useful LongevityNext model case because it shows how a company-reported human-aging biology narrative is translated into conventional therapeutic development signals, trial registries, and public-company disclosure. This page maps those signals without treating them as clinical validation, investment analysis, or proof of cardiovascular, obesity, retinal, or longevity benefit.
Platform / Pipeline Overview
| Program | Mechanism / pathway | Stage | Source type | Evidence boundary | Caution note |
|---|---|---|---|---|---|
| BGE-102 / NLRP3 | NLRP3 inflammasome pathway | Phase 2 QUELL-CV recruiting per registry; Phase 1 statements company-reported | BioAge IR + ClinicalTrials.gov | Pipeline and trial-design facts, not clinical outcome evidence | Does not establish cardiovascular-event reduction, efficacy, approval likelihood, dosing guidance, or longevity benefit. |
| APJ program | APJ pathway | Company-reported preclinical / lead-optimization background | BioAge official program page | Company-reported program context | Not independently validated clinical evidence and not a future-success claim. |
| Azelaprag / STRIDES context | APJ agonist program context | STRIDES listed as terminated; separate PK study completed per registry | ClinicalTrials.gov + company/context sources | Trial-status and company-event context | Included as neutral caution, not a generalized safety or efficacy conclusion. |
Trial Links
| Registry ID | Status / phase | Relationship to company | What it supports | What it does not prove |
|---|---|---|---|---|
| NCT07656727 | Recruiting / Phase 2 | BGE-102 / QUELL-CV study sponsored by BioAge Labs | Registry-backed trial design, sponsor/status, and endpoint context | Does not prove clinical benefit, cardiovascular outcome reduction, approval likelihood, or longevity effect. |
| NCT06515418 | Terminated / Phase 2 | Azelaprag / STRIDES context | Registry-backed termination/status context | Does not support broad safety, efficacy, or commercial conclusions. |
| NCT06141889 | Completed / Phase 1 | Azelaprag pharmacokinetics study context | Registry-backed study-design/status context | Does not establish therapeutic, longevity, or clinical-outcome benefit. |
Source Posture
Company official / IR sources
Useful for identity, program names, pipeline positioning, and company-reported milestones. Not independent validation.
ClinicalTrials.gov sources
Useful for trial IDs, sponsor, phase, status, design, and endpoints. Registration does not imply efficacy or outcome evidence.
IR SEC filings index
Supports the presence of public-company filing context. Direct SEC browse/search links that failed are not used as source anchors.
Independent context
BioPharma Dive context is retained for company-event coverage, not as proof of program efficacy or future success.
Excluded source anchors
Reuters links and failed direct SEC browse/search links remain excluded from the visible source set.
Evidence / Claim Boundary
Company-reported
Program and platform statements are attributed to BioAge unless a registry or independent source supports the specific claim.
Registry-supported
Trial registry facts support design/status context only; they do not establish results or clinical benefit.
Independent context
Independent trade coverage can provide event context but is not treated as clinical validation.
Not clinical outcome evidence
The prototype does not infer cardiovascular-event reduction, obesity outcomes, retinal outcomes, or longevity benefit.
Not investment advice
Public-company and capital-market context is informational only and does not assess stock value or investment merit.
Timeline / Milestones
-
BioAge FY2025 results / business-update source retained
BioAge IR
Used for company-reported context, not investment analysis.
-
BioAge Q1 2026 results / business-update source retained
BioAge IR
Used for company-reported context and source posture only.
-
QUELL-CV / NCT07656727 appears as recruiting Phase 2
ClinicalTrials.gov
Supports trial-design/status context, not efficacy.
-
STRIDES / NCT06515418 appears as terminated Phase 2
ClinicalTrials.gov
Neutral context only; no broad safety or efficacy conclusion.
-
Azelaprag PK study / NCT06141889 appears completed Phase 1
ClinicalTrials.gov
Supports study-design/status context only.
Related Intelligence
NCT07656727
QUELL-CV / BGE-102 registry context for BioAge; supports trial design/status only.
NCT06515418
STRIDES / azelaprag registry context; included as neutral terminated-trial context.
NCT06141889
Azelaprag pharmacokinetics study context; not a longevity-benefit claim.
NLRP3 / inflammatory pathway context
Shown as program biology context only; a dedicated mechanism/intervention record is still needed before stronger internal linking.
What This Does Not Prove
No efficacy certainty
The page does not establish that BGE-102, azelaprag, APJ, or BioAge platform claims are clinically effective.
No approval or future-success claim
Pipeline, registry, and IR milestones are not approval predictions or development-success claims.
No cardiovascular outcome claim
Biomarker or trial-design context is not treated as cardiovascular-event reduction evidence.
No treatment or dosing guidance
The profile is not medical advice and does not support patient use, prescribing, dosing, or suitability decisions.
No investment merit
Public-company and filing context is not an investment recommendation or valuation assessment.
Source Table
| Source | Type | Supports | Limitation | Link |
|---|---|---|---|---|
| BioAge main site | Official company | Company identity and broad platform positioning | Company-controlled source; not independent validation. | Open source |
| BioAge overview page | Official company | Company-described platform and business overview | Company-controlled source. | Open source |
| BioAge NLRP3 / BGE-102 page | Official company | Program description and company-reported NLRP3 context | Does not establish clinical outcome evidence. | Open source |
| BioAge APJ page | Official company | APJ program background | Company-reported/preclinical/lead-optimization context. | Open source |
| BioAge IR press release index | Company IR | Navigation to company-reported milestones and business updates | Company-controlled and may be selective. | Open source |
| BioAge IR SEC filings index | Filing index | Public-company filing context location | Index only; failed direct SEC links are not used as anchors. | Open source |
| ClinicalTrials.gov NCT07656727 | Trial registry | QUELL-CV / BGE-102 status, phase, sponsor, design context | Registration does not imply efficacy. | Open source |
| ClinicalTrials.gov NCT06515418 | Trial registry | STRIDES / azelaprag status and design context | Terminated status is neutral context, not a broad conclusion. | Open source |
| ClinicalTrials.gov NCT06141889 | Trial registry | Azelaprag pharmacokinetics study status/design context | Does not establish therapeutic or longevity benefit. | Open source |
| BioPharma Dive context | Independent context | Company-event context around BioAge programs | Context only; not proof of efficacy or investment merit. | Open source |
| BioPharma Dive NLRP3 context | Independent context | Company-event context for NLRP3/BGE-102 coverage | Context only; not clinical validation. | Open source |